Novartis AG (NVS)
NYSE • Healthcare
August 21, 2026 at 16:56 UTC
About Novartis AG
Novartis AG (NYSE: NVS) is a global pharmaceutical company in healthcare that develops and sells prescription drugs and related medicines, with $54.8 billion of revenue in FY2025. Its business spans innovative branded therapies, generic and biosimilar medicines, and manufacturing capabilities that reach patients, healthcare professionals, and other institutional buyers worldwide.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Novartis AG's Technical Indicators Summary
NVS is showing a constructive technical picture driven by bullish moving-average alignment and positive momentum, while trend strength remains muted. The stock sits comfortably above its short- and long-term averages, and MACD and momentum readings are supportive even as oscillators are neutral-to-overbought. ADX indicates a weak trend, and volume-based measures are soft, so price action is doing the heavy lifting rather than conviction buying. Volatility is moderate at under 2% ATR, and the classic pivot sits slightly lower, acting as near-term support. Technical takeaway: Buy.
| Indicator | Value |
|---|---|
RSI (14) | 57.38 |
Stochastic %K (14, 3, 3) | 80.26 |
CCI (20) | 86.58 |
WPR (14) | -15.96 |
Momentum (10) | 2.61 |
MFI | 45.55 |
MACD Level (12, 26) | 0.65 |
Bollinger Bands | $149.89 - $161.07 |
ATR (14) | $3.14 (1.97%) |
ADX (14) | 11.79 |
OBV | 8,326,499 |
Classic Pivot Point | $157.15 |
Fibonacci Pivot Point | $157.15 |
Simple Moving Averages | $148.25 - $155.48(5 indicators) |
Exponential Moving Averages | $146.53 - $155.76(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
Price action at the open was nearly flat, with NVS easing -0.04% to 156.17 compared with yesterday’s 156.24. Early volumes are extremely muted, with NVS trading at just 0.25× its typical pace. NVS benefits as cardiovascular data build investor interest.
Trading Volume
Below 10d avg (1.5M)
363.3K
vs S&P 500 Today
Outperforming Market
+1.45%
52-Week Position
Upper range
76.6%
Updated: August 21, 2026 at 14:54 UTC
Quote Summary
NVS Headlines
Novartis lifts Q2 profit, reaffirms 2026 outlook
July 21, 2026
Novartis to acquire Myricx Bio for up to $1.5bn
July 6, 2026
Azoria ETFs shut, Novartis India stake sold, tariff shock
February 20, 2026
Live Nation, PTC, AES Lead Busy Earnings and Energy News
February 19, 2026